Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Share-based Compensation (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Share-based Compensation for 12 consecutive years, with $12.4 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 49.4% to $12.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.6 million through Dec 2025, up 37.98% year-over-year, with the annual reading at $40.8 million for FY2025, 37.38% up from the prior year.
  • Share-based Compensation hit $12.4 million in Q4 2025 for Viking Therapeutics, up from $7.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $13.5 million in Q2 2025 to a low of $893000.0 in Q4 2022.
  • Historically, Share-based Compensation has averaged $5.4 million across 5 years, with a median of $4.2 million in 2023.
  • Biggest five-year swings in Share-based Compensation: tumbled 47.47% in 2022 and later surged 336.73% in 2023.
  • Year by year, Share-based Compensation stood at $1.7 million in 2021, then crashed by 47.47% to $893000.0 in 2022, then soared by 336.73% to $3.9 million in 2023, then skyrocketed by 112.82% to $8.3 million in 2024, then soared by 49.4% to $12.4 million in 2025.
  • Business Quant data shows Share-based Compensation for VKTX at $12.4 million in Q4 2025, $7.3 million in Q3 2025, and $13.5 million in Q2 2025.